Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci

被引：26

作者：

Eliopoulos, GM ^{[1
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Boston, MA 02215 USA

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 2005年 / 24卷 / 12期

关键词：

D O I：

10.1007/s10096-005-0055-1

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

As clinicians increasingly contend with infections due to staphylococci or enterococci resistant to, or failing treatment with, traditional antimicrobial agents, understanding the potential roles of older as well as more recently introduced antimicrobial agents becomes important. Older agents, such as clindamycin and trimethoprim-sulfamethoxazole, have been used to treat infections due to community-acquired methicillin-resistant Staphylococcus aureus. Among the licensed agents, quinupristin-dalfopristin, linezolid, daptomycin, and tigecycline are active in vitro against most strains of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium, but these agents differ in their approved clinical indications. New agents currently under investigation may further expand treatment options.

引用

页码：826 / 831

页数：6

共 68 条

[1] Mechanism of action of oritavancin and related glycopeptide antibiotics [J].

Allen, NE ;

Nicas, TI .

FEMS MICROBIOLOGY REVIEWS, 2003, 26 (05) :511-532

[2] The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].

Arbeit, RD ;

Maki, D ;

Tally, FP ;

Campanaro, E ;

Eisenstein, BI .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681

[3] Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid [J].

Babcock, HM ;

Ritchie, DJ ;

Christiansen, E ;

Starlin, R ;

Little, R ;

Stanley, S .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (09) :1373-1375

[4] Prolonged colonization with vancomycin-resistant enterococcus faecium in long-term care patients and the significance of "clearance" [J].

Baden, LR ;

Thiemke, W ;

Skolnik, A ;

Chambers, R ;

Strymish, J ;

Gold, HS ;

Moellering, RC ;

Eliopoulos, GM .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (10) :1654-1660

[5] Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program [J].

Birmingham, MC ;

Rayner, CR ;

Meagher, AK ;

Flavin, SM ;

Batts, DH ;

Schentag, JJ .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) :159-168

[6] Community-adapted methicillin-resistant Staphylococcus aureus (MRSA):: Population dynamics of an expanding community reservoir of MRSA [J].

Carleton, HA ;

Diep, BA ;

Charlebois, ED ;

Sensabaugh, GF ;

Perdreau-Remington, F .

JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (10) :1730-1738

[7]

Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P322

[8] In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria [J].

Chamberland, S ;

Blais, J ;

Hoang, M ;

Dinh, C ;

Cotter, D ;

Bond, E ;

Gannon, C ;

Park, C ;

Malouin, F ;

Dudley, MN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (05) :1422-1430

[9] Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus [J].

Chambers, HF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :884-888

[10] Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus [J].

Charles, PGP ;

Ward, PB ;

Johnson, PDR ;

Howden, BP ;

Grayson, ML .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) :448-451

← 1 2 3 4 5 6 7 →